Articles tagged with Breast Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers have found that trastuzumab can improve outcomes for bladder cancer patients with HER2 amplification, a known driver of aggressive tumors. The study identified 15% of MPUC patients had HER2 amplification, leading to faster growth and higher recurrence rates.
Research published in PLOS ONE found that high doses of folic acid supplements promote the growth of existing breast cancer cells in rats. The study suggests a potential link between folic acid consumption and increased risk of developing breast cancer, particularly among women taking multivitamins or supplements.
Researchers identified four subtypes of HER2+ breast cancer, including Luminal A, Luminal B, HER2-enriched, and Basal-Like, with varying responses to anti-HER2 therapy and chemotherapy. The study suggests that personalized treatment strategies may improve treatment outcomes for patients.
Researchers identified critical complex mechanisms involved in TNBC metastasis, including the interaction between WAVE3 and TGF-β proteins. The discovery has the potential to develop new treatments to kill metastatic tumors in TNBC, with the goal of moving into clinical trials within three years.
Patients with multiple sclerosis in Taiwan may be at a significantly higher risk of developing cancer, particularly breast cancer, according to a recent study published in European Journal of Neurology. The nationwide population-based cohort study found an 85% increased risk of cancer development among MS patients compared to controls.
Researchers found a correlation between DNA methylation levels and breast cancer risk in high-risk families. High levels of DNA methylation were associated with increased breast cancer clustering within families.
Cancer death rates have declined by 20% over the past two decades, with middle-aged black men experiencing a 50% reduction in mortality. The American Cancer Society estimates that there will be 1,665,540 new cancer cases and 585,720 cancer deaths in 2014.
Researchers found that alphaB-crystallin enhances breast cancer cells' ability to penetrate the blood-brain barrier and form metastases in the brain. Tumors expressing this protein had a poorer prognosis and were more likely to be triple-negative breast cancers.
A novel breast-cancer therapy has been developed that partially reverses the cancerous state in cultured breast tumor cells and prevents cancer development in mice. The therapy uses a sophisticated method to identify genes that drive cancer and blocks them using RNA interference, offering new hope for early-stage treatment without surg...
Researchers found that chronic preoperative pain, chemotherapy, and depression were linked to persistent pain in breast cancer patients 12 months post-surgery. The study included over 800 women with nonmetastasized breast cancer treated between 2006-2010.
Researchers at Johns Hopkins University have discovered that low oxygen conditions inside tumors trigger the production of proteins RhoA and ROCK1, enabling breast cancer cells to become mobile and invasive. High levels of these proteins are associated with poorer patient outcomes and increased tumor spread.
Younger women with aggressive tumors and higher recurrence risks are less likely to receive radiotherapy after breast conserving surgery, according to a nationwide database analysis. Factors affecting non-compliance among younger women include family structures and region of residence.
A small study found that both real and sham acupuncture eased hot flashes and side effects of anticancer drug treatment in postmenopausal breast cancer patients. Researchers noted improvements in depression, quality of life, and menopausal symptoms in both groups.
Researchers at the University of Maryland School of Medicine found that both real and sham acupuncture reduce hot flashes and other symptoms in breast cancer patients taking an aromatase inhibitor. The study suggests that acupuncture may be a reasonable alternative to drug therapy with fewer side effects.
A new analysis found that both real and sham acupuncture may help alleviate breast cancer drug side effects. Patients who received real acupuncture experienced less joint/muscle discomfort and menopausal symptoms compared to those receiving sham acupuncture.
A new analysis found that both real and sham acupuncture treatments alleviate side effects of breast cancer drugs, including hot flashes and joint/muscle pain. Women who received real acupuncture had a greater reduction in symptoms if they were African American.
A survey of over 2,500 Americans revealed that Angelina Jolie's public announcement about her preventive double mastectomy did not translate to increased knowledge of breast cancer risk and the BRCA gene mutation, highlighting a need for further education.
Eating a tomato-rich diet for 10 weeks increased adiponectin levels by 9 percent in postmenopausal women, reducing breast cancer risk. Regular consumption of fruits and vegetables is believed to promote breast cancer prevention in at-risk populations.
A new research study at Cedars-Sinai Medical Center is investigating the predictors, mechanisms for development, and persistence of post-treatment fatigue in breast cancer patients. The study will examine biological, behavioral, and social risk factors to identify women at high risk for fatigue.
Berkeley Lab researchers show that aerobic glycolysis is not the consequence of cancerous activity but a cancerous event. Increased sugar uptake in breast cells activates oncogenic signaling pathways, leading to cancerous growth. The study provides possible new targets for diagnosis and therapeutics.
A study by Manchester scientists found that women who undergo risk-reducing surgery have increased survival rates compared to those who don't. The research suggests that removing ovaries and fallopian tubes can reduce the risk of both ovarian and breast cancer by half.
A new clinical trial design, I-SPY 2, has enabled researchers to quickly identify effective treatments for high-risk breast cancer patients. Veliparib has shown a 91% probability of success in triple-negative breast cancer patients.
A phase III clinical trial found that adding ramucirumab to chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced breast cancer. Researchers will analyze biomarkers to identify potential subgroups of patients who may benefit from the therapy.
A new trial found that adding chemotherapy carboplatin and the molecularly targeted drug veliparib to standard presurgery chemotherapy improved pathologic complete response rates for patients with triple-negative breast cancer. The study's adaptive design showed a 92% predictive probability of success in a phase III trial.
A phase III clinical trial presented at the 2013 San Antonio Breast Cancer Symposium found that bisphosphonate zoledronate had no effect on event-free survival in women with chemoresistant breast cancer. Researchers also reported that patients with hormone receptor-positive disease were more common, which may impact treatment outcomes.
A nationwide study found that adding carboplatin to standard chemotherapy significantly increased tumor shrinkage in patients with triple-negative breast cancer. The results suggest that carboplatin could be used as an alternative or addition to current treatments.
A randomized, phase II clinical trial found that adding carboplatin and/or bevacizumab to standard presurgery chemotherapy increased the number of patients with no residual cancer detected at surgery. The study showed significant increases in pathologic complete response rates for patients treated with these combinations.
A phase III clinical trial found that switching to a different chemotherapy did not improve overall survival or time to progression for women with metastatic breast cancer and elevated circulating tumor cells. Patients with low CTCs before starting chemotherapy had a median overall survival of 35 months, while those with elevated CTCs ...
A new study published in The Lancet found that anastrozole significantly reduced the risk of breast cancer in postmenopausal women with a family history or other risk factors. After five years, 40 women in the treatment group developed breast cancer compared to 85 in the placebo group.
A study from the University of Texas M.D. Anderson Cancer Center found that 37% of younger, early-stage breast cancer patients underwent unnecessary staging tests, including PET, CT, and tumor markers. Women with PPO insurance coverage and those under 35 years old were at higher risk of receiving these tests.
A phase II clinical trial found that adding dasatinib to letrozole therapy doubled the time before disease progression for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. Progression-free survival was also improved by 10 months compared to letrozole alone.
A Mayo Clinic study found that endoxifen, an active metabolite of tamoxifen, is safe and shows anti-tumor activity in early-stage trials. The findings suggest a potential new treatment for estrogen-positive breast cancer patients who don't respond to standard hormonal therapies.
A randomized trial found that exercise reduced worst pain scores by 20% among women taking AIs, with a dose-response effect on pain relief. The study suggests exercise as a potential clinical intervention to improve AI-associated joint pain and adherence.
Researchers used deep genome sequencing to study changes in breast cancer tumors after brief exposure to therapy, finding a reduction in mutated genes that can predict future clinical outcomes. The study's findings have the potential to personalize treatment plans for individual patients and improve patient outcomes.
A double-blind, randomized trial found that anastrozole significantly reduced breast cancer incidence among postmenopausal women at high risk for developing the disease. The study showed a 53% reduction in breast cancer incidence with few side effects.
Researchers identified three types of mutations in the estrogen receptor gene ESR1 that cause resistance to hormone therapy, including gene amplification, point mutation, and translocation. These findings provide insights into how to develop targeted treatments for drug-resistant breast cancer.
Research found that women with HER2- and hormone receptor-positive breast cancer treated with neoadjuvant therapy had lower pathologic complete response rates if their tumors had PIK3CA gene mutations. These mutations were more common in HER2-positive breast cancers.
A study by Dana-Farber Cancer Institute and Yale University found that moderate daily exercise can decrease joint pain in postmenopausal women taking aromatase inhibitors for breast cancer. After a year, joint pain scores decreased by 20% in the exercise group compared to 3% in the non-exercise group.
Researchers at Johns Hopkins Medicine have identified a unique class of breast cancer cells that lead the invasion process into surrounding tissues. The team found that these 'leader cells' express a protein called K14, which is essential for their invasive behavior and may be a new target for therapy.
Researchers at Jefferson Breast Care Center found that genomic tests like MammaPrint and BluePrint provide more accurate classification of breast cancer subtypes than traditional methods. These tests enable better identification of patients who benefit from chemotherapy, reducing unnecessary treatment risks.
A new multi-gene test can identify breast cancer patients at high risk of developing aggressive triple-negative cancers. The test analyzes genetic signatures associated with poor prognosis, which may reveal potential targets for new drugs and therapies.
A nearly 20-year observational study found that regular vigorous exercise reduces the risk of developing estrogen receptor-negative (ER-) breast cancer in black women. The study, which involved over 44,700 black women nationwide, showed a significant protection against this aggressive subtype of breast cancer.
A randomized controlled trial found that surgical removal of the primary tumor and axillary lymph nodes did not improve overall survival in women with metastatic breast cancer. The study suggests that conventional wisdom may need to be revised for patients who have metastatic breast cancer.
A re-examination of large breast cancer screening studies reveals a substantial reduction in mortality rates for women undergoing screening. The results suggest that the estimates of women needed to be screened to prevent one death vary significantly, but can be standardized to a similar scenario.
Researchers found that women with HER2-positive breast cancer who had high levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab. This biomarker can help identify patients most likely to benefit from this therapy.
Researchers at Dana-Farber Cancer Institute found a combination chemotherapy and targeted therapy reduced cancer recurrence in women with small, HER2-positive tumors. After 3.6 years, only 0.5% of patients experienced cancer recurrence.
Researchers have found that omitting radiotherapy in older patients with hormone-receptor positive breast cancer who undergo surgery and hormone therapy is a viable option, resulting in a lower rate of unnecessary treatment. The study suggests that these patients are at low risk of recurrence, making radiotherapy optional.
The NeoALTTO trial analyzed event-free and overall survival in patients with HER2-positive primary breast cancer. The study found improved pathologic complete response rates, which may translate to better long-term outcomes.
A new study has identified a highly effective treatment option for patients with HER2-positive breast cancer, combining docetaxel, carboplatin, and trastuzumab. The treatment regimen demonstrates improved outcomes and a safer profile compared to anthracycline-based therapies, which are currently dominated in breast cancer treatment.
A new study found that Herceptin plus Taxol is highly effective in treating lower-risk breast cancer patients, with a 98.7% success rate of being cancer-free for at least three years. The treatment had minimal side effects, with only 3.2% experiencing severe neuropathy.
African-American women with breast cancer are more likely to develop aggressive forms of the disease at a younger age. Researcher Ritu Aneja has found a protein called HSET as a potential biomarker for identifying these cancers, which could lead to customized treatment plans.
VIB researchers have identified a protein, Nrp1, that suppresses the anti-tumor activity of macrophages. Blocking Nrp1 restores this immune response, leading to reduced tumor growth and improved prognosis.
Researchers found a strong association between high 2-HG levels, DNA methylation patterns, and poor survival outcomes in African-American breast cancer patients. The study identified a distinct breast cancer subtype with elevated 2-HG levels that was associated with reduced survival.
Researchers discovered an association between oncometabolite 2-hydroxyglutarate (2-HG) levels and DNA methylation patterns with breast cancer prognosis. Chloroquine treatment was found to limit osteoclast generation, suggesting potential therapeutic applications.
A year of resistance and impact training can help older breast cancer survivors preserve bone density, even with less exercise. Muscle strength declines more quickly than bone density and may require continued participation in a supervised exercise program.
A study of 1,344 women diagnosed with breast cancer between 2004 and 2011 found that those with interruptions in health insurance coverage or low income levels were significantly more likely to receive non-concordant treatment. Women with lower incomes had a higher likelihood of nonconcordance with National Comprehensive Cancer Network...
A computer model found that genetic screening for breast cancer risk in conjunction with MRI can reduce cancer deaths and identify a population at an intermediate risk. The study compared two tests to categorize patients by lifetime risk, finding the 7SNP test was most cost-effective for those with an intermediate risk.
A study found that women who had more frequent screening mammography had a significantly lower rate of lymph node positivity, improving patient prognosis. The researchers suggest that following guidelines recommending annual screening beginning at age 40 may benefit breast cancer patients.
Researchers assessed MR-guided focused ultrasound (MRgFUS) in 12 patients with invasive ductal breast cancer. The procedure proved safe and effective, with 10 patients showing no residual disease post-surgery. Continuous MRI monitoring allowed for precise temperature control during the ablation process.
A recent study published in The Lancet Oncology found that cancer survival rates still differ significantly between European countries, with Nordic countries having the best survival rates for most cancers. However, there is evidence of narrowing gaps between east and west, particularly for breast and prostate cancers.